Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Fanny S KrebsComputer-aided molecular engineering group, Department of Fundamental Oncology, Lausanne University, Ludwig Lausanne Branch, 1066 Epalinges, Switzerland.
Camille GérardPrecision Oncology Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.ORCID 0000-0002-6007-1746
Alexandre WickyPrecision Oncology Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Veronica Aedo-LopezService of Medical Oncology, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Edoardo MissiagliaSIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Bettina BisigUniversity Institute of Pathology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Mounir TrimechUniversity Institute of Pathology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Olivier MichielinPrecision Oncology Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Krisztian HomicskoPrecision Oncology Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Vincent ZoeteComputer-aided molecular engineering group, Department of Fundamental Oncology, Lausanne University, Ludwig Lausanne Branch, 1066 Epalinges, Switzerland.ORCID 0000-0002-2336-6537
University of Lausanne · CHSIB Swiss Institute of Bioinformatics · CH
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
We report a case of an uveal melanoma patient with
Indexed as
MutationAmino Acid SequenceAntineoplastic AgentsFemaleGTP-Binding Protein alpha Subunits, Gq-G11HumansMelanomaMiddle AgedModels, MolecularMutant ProteinsProtein ConformationProtein StabilityPyridonesPyrimidinonesReceptor, Fibroblast Growth Factor, Type 4Sequence HomologyAntineoplastic AgentsFGFR4 protein, humanGNAQ protein, humanGTP-Binding Protein alpha Subunits, Gq-G11Mutant ProteinsPyridonesPyrimidinonesReceptor, Fibroblast Growth Factor, Type 4trametinibFGFR4GNAQmolecular modellingmutationprecision oncology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Trametinib Induces the Stabilization of a Dual · full record | OpenQuestion